Skip to content ↓

Lima to lead HR's new three-person diversity team

Vice President of Human Resources Laura Avakian has announced the creation of the Staff Diversity, Affirmative Action and Equal Employment Opportunity management team, and the appointment of Philip Lima as coordinator of staff diversity initiatives.

The new team consists of Wendy Williams, director of staffing services; Robert Martinez, recruiting specialist; and Lima, who also will serve as MIT's central contact for affirmative action and equal opportunity issues involving staff.

"The team will seek to build on the significant gains in the management of the Institute's staff affirmative action and equal opportunity policies achieved by many dedicated individuals, including Regina Caines, the recently retired director of Affirmative Action, Equal Opportunity and Diversity Programs," said Avakian. "The MIT community profited greatly from the unique combination of Regina's expertise and leadership in the areas of affirmative action and equal opportunity and her experience as a research scientist."

Lima, who has managed MIT's retirement programs, will coordinate the creation of a new Council on Staff Diversity to be led by Executive Vice President John R. Curry and Avakian. He also will work on legal compliance issues.

The council will sponsor staff affirmative action and diversity management activities, including a thorough review of the "serious search process" for staff, said Avakian, MIT's equal opportunity officer.

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story